Breast cancer has been diagnosed and treated in approximately 2 million women living in the United States, and the incidence of prostate cancer—now second in prevalence to lung cancer in men—has shown a slow but steady increase.1 Cancers of the breast and prostate are hormone-dependent, and this has been the focus of intense research that has resulted in the new, effective adjuvant therapies that are in use today.
Targeted Drug Combination Reveals New Activity in Brain Tumors
December 28th 2021A combination of two targeted cancer drugs showed unprecedented, “clinically meaningful” activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute.